IDEXX Laboratories Reports Strong Q3 2026 Growth and Raises Full Year Guidance
IDEXX Laboratories (IDXX) delivered a strong third quarter for 2026, reporting revenue of $1.214 billion, which represents 10% organic growth. This performance was primarily driven by robust volume expansion in the Companion Animal Group (CAG) diagnostics segment and successful new product launches. Despite a 1.8% decrease in U.S. same-store clinical visits, diagnostic revenue significantly outperformed visit trends, demonstrating high testing intensity per visit. The company demonstrated improved profitability with an operating margin of 33.1% and GAAP EPS increasing 18% year-over-year to $4.01. Following these results, IDEXX raised its full-year 2026 guidance for both revenue and earnings per share. While the acquisition of CoVet is expected to provide minor revenue contributions, management noted near-term margin pressures due to integration costs and potential foreign exchange volatility.
Tickers: $IDXX
Topics: Companion Animal Group Diagnostics Revenue GAAP EPS Operating Margin Revenue Growth